US14817C1071 - Common Stock
CASSAVA SCIENCES INC
NASDAQ:SAVA (3/28/2024, 8:00:02 PM)
After market: 20.05 -0.24 (-1.18%)20.29
-0.13 (-0.64%)
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 26 full-time employees. The company went IPO on 2000-07-14. The firm is engaged in the detection and treatment of neurodegenerative diseases, such as Alzheimer’s disease. The firm develops pharmaceutical product candidates that offer improvements to patients and healthcare professionals. The firm has two biopharmaceutical assets under development, including its lead therapeutic product candidate, called simufilam, is an oral treatment for Alzheimer’s disease dementia, which is under Phase III clinical studies; and its lead investigational diagnostic product candidate, called SavaDx, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. Simufilam is a proprietary small molecule (oral) drug, which targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. SavaDx is designed as an antibody-based detection system for altered filamin A (FLNA).
CASSAVA SCIENCES INC
6801 N Capital Of Texas Highway, Building 1; Suite 300
Austin TEXAS 78731
P: 15125012444
CEO: Remi Barbier
Employees: 26
Website: https://www.cassavasciences.com/
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between...
/PRNewswire/ -- (PRNEWSWIRE) Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. ("Cassava" or the "Company")...
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
WHY: NEW YORK, NY - (NewMediaWire) - March 25, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between August 18, 2022 and October 12, 2023, both dates inclusive (the “Class Period”) of the important April 2, 2024 lead plaintiff deadline.
Here you can normally see the latest stock twits on SAVA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: